Pliant Therapeutics vs Zentalis Pharmaceuticals
PLRX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PLRX and ZNTL compare
Zentalis Pharmaceuticals is the larger company, worth 2.6 times as much as Pliant Therapeutics ($107M against $40.9M).
Zentalis Pharmaceuticals scores higher on the StockData Score (6 against 3 for Pliant Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PLRX | ZNTL |
|---|---|---|
| Size and price | ||
| Market cap | $40.9M | $107M |
| Share price | $0.660 | $1.49 |
| Change, 1 year | −60.7% | 12.0% |
| Change, 5 years | −95.4% | −98.0% |
| Beta (5Y) | 0.95 | 5.80 |
| Employees | 49 | 106 |
| StockData Score | ||
| Total score | 3 | 6 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.3× (better) | 0.7× |
| FCF yield | −173% | −120% (better) |
| Profitability | ||
| Return on equity | −50.3% (better) | −66.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −102.5× | – |
| Current ratio | 9.90 (better) | 4.82 |
| Altman Z-score | −6.85 (better) | −8.91 |
| Piotroski F-score | 2 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.7% | 66.1% |
| Held by insiders | 13.0% | 58.0% |
| Insider net buying, 12 months | −$164K | $12.8M (better) |
| Short interest, % of float | 9.1% | 16.7% |
Go deeper
- PLRX stock overview
- PLRX income statement
- PLRX valuation and score
- ZNTL stock overview
- ZNTL income statement
- ZNTL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.